Preventive Effect of Mineralocorticoid Receptor Antagonists Against Proteinuria Induced by Atezolizumab Plus Bevacizumab Therapy in Hepatocellular Carcinoma: A Multicenter Retrospective Study
Hepatology Research · 2026-08 · 56 (8) · 1225-1234
DOI: 10.1111/hepr.70176 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hepatology Research, online erschienen am 04.04.2026. Verfasst von Tomoki Hori und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Nara Prefecture General Medical Center, Nara, Japan. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Aim
Mineralocorticoid receptor antagonists (MRAs) reduce proteinuria in chronic kidney disease, but their role in preventing bevacizumab‐induced proteinuria remains uncertain. This study aimed to assess whether MRAs prevent proteinuria caused by atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
Methods
The present retrospective study included patients with advanced hepatocellular carcinoma who received atezolizumab plus bevacizumab between September 2020 and December 2023 at five institutions in Japan. The primary outcome was the time to onset of grade ≥ 2 proteinuria during the first 6 months of bevacizumab treatment.
Results
Among 177 patients, 26 received MRAs and 151 did not. The onset of grade ≥ 2 proteinuria occurred significantly later in the MRA group than in the non‐MRA group ( p = 0.018). In multivariate Cox hazard analysis, diabetes (hazard ratio [HR] = 1.81, 95% confidence interval [CI]: 1.00–3.25, p = 0.049), higher average systolic blood pressure (HR = 2.08, 95% CI: 1.16–3.73, and p = 0.014), and MRA use (HR = 0.21, 95% CI: 0.047–0.90, and p = 0.035) were independently associated with time to grade ≥ 2 proteinuria. Bevacizumab interruption due to proteinuria within 6 months was lower in the MRA group than in the non‐MRA group (0% vs. 13.2% and p = 0.049).
Conclusions
MRA can suppress moderate or greater proteinuria induced by atezolizumab plus bevacizumab therapy and reduce the rate of bevacizumab interruption.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy, Nara Prefecture General Medical Center, Nara, Japan.
- Department of Pharmacy, Kobe University Hospital, Kobe, Japan.
- Department of Integrated Clinical and Basic Pharmaceutical Science, Okayama University, Kita-ku, Okayama, Japan.
- Department of Pharmacy, Nara Medical University Hospital, Nara, Japan.
- Department of Pharmacy, Tenri Hospital, Nara, Japan.
- Department of Pharmacy, Kindai University Nara Hospital, Nara, Japan.
ORCID-Profile: Tomoki Hori, Kei Moriya
Zitieren
APA
Hori, T., Yamamoto, K., Aoi, H., Koizumi, Y., Kuromatsu, M., Fukui, A., Okamoto, H., Hirata, A., Shinmori, K., Imanaka, Y., Namba, M., Nakanishi, K., Kitamura, S., Tsushima, H., Yano, I., Moriya, K., Matsui, M., & Ikushima, S. (2026). Preventive Effect of Mineralocorticoid Receptor Antagonists Against Proteinuria Induced by Atezolizumab Plus Bevacizumab Therapy in Hepatocellular Carcinoma: A Multicenter Retrospective Study. Hepatology Research, 56(8), 1225-1234. https://doi.org/10.1111/hepr.70176
Vancouver
Hori T, Yamamoto K, Aoi H, Koizumi Y, Kuromatsu M, Fukui A, et al. Preventive Effect of Mineralocorticoid Receptor Antagonists Against Proteinuria Induced by Atezolizumab Plus Bevacizumab Therapy in Hepatocellular Carcinoma: A Multicenter Retrospective Study. Hepatology Research. 2026;56(8):1225-1234. doi:10.1111/hepr.70176
BibTeX
@article{Hori2026,
author = {Hori, Tomoki and Yamamoto, Kazuhiro and Aoi, Hiroshi and Koizumi, Yusuke and Kuromatsu, Makoto and Fukui, Aiko and Okamoto, Hiroyo and Hirata, Atsushi and Shinmori, Kentaro and Imanaka, Yuki and Namba, Miyu and Nakanishi, Keisuke and Kitamura, Syunsuke and Tsushima, Hideo and Yano, Ikuko and Moriya, Kei and Matsui, Masaru and Ikushima, Shigeki},
title = {Preventive Effect of Mineralocorticoid Receptor Antagonists Against Proteinuria Induced by Atezolizumab Plus Bevacizumab Therapy in Hepatocellular Carcinoma: A Multicenter Retrospective Study},
journal = {Hepatology Research},
year = {2026},
volume = {56},
number = {8},
pages = {1225--1234},
doi = {10.1111/hepr.70176}
}
EUVIMED